TEM Tempus AI, Inc Profit After Tax

Corporate emblem and logo of Tempus AI, Inc. (TEM)

High initial expenditures on the Tempus AI, Inc (TEM) AI platform are creating financial pressure, yet the firm's net income on this GURU.Markets chart reflects a trend where the -0.25 parameter determines the metric's magnitude. The synthesis of genetics and neural networks for targeted therapy mitigates these risks. Profit growth is supported by the largest DNA database and a strategic alliance with Big Pharma in oncology.

Tempus (TEM) Company Net Income: for the period 06/15/2024 - 10/29/2026

Financial and market metric breakdowns for Tempus AI Inc (TEM)

- price and consensus price forecast:
Stock Quotes Tempus AI|TEM - Price Target Chart
- market capitalization data:
Market Valuation Tempus Labs|TEM - Real Price to Acquire Entire Company
- issuer book value statistics:
Book Value per Share Tempus|TEM - Company Book Value|Market Capitalization to Book Value tempus.com|TEM - Cumulative Company Assets
- debt and solvency information:
All Debt to Shareholders' Equity Ratio Tempus AI, Inc|TEM - Long-Term Debt to Capital|Short-Term Debt to Capital Tempus Labs|TEM - Company Aggregate Debts|Debts to Net Assets Tempus Labs|TEM - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Tempus|Interim Coverage Ratio tempus.com
- earnings and market multiples details:
TEM - Company Net Income
Fundamental valuation:TEM - tempus.com
Manufactured products of Tempus AI Inc

Monitoring net income is critical for Tempus AI, Inc (TEM) amid fierce competition with tech giants and laboratories. This indicator captures the final financial result after deducting all operating and tax expenses. By analyzing the company's profit, an investor sees the business's immediate market reaction to US market turbulence. High volatility in the curve signals risks of deep drawdowns. The stability of this metric determines the company's viability within the high-tech sector.

Key competitors

Net Income Qiagen Corp|Company Net Income Ionis Pharmaceuticals|repligen.com - Profit After Tax|Net Income RNA (Avidity Biosciences, Inc.)|Net Profit CRISPR Therapeutics Inc (CRSP)|Company Net Income Sema4 WGS|Net Financial Result Ultragenyx Corp (RARE)|BEAM: Net Income|Final Profit SRPT (sarepta.com)|TWST: Net Profit|10x Genomics Inc (TXG) - Net Profit|NTLA (Intellia) - Net Profit|Stoke Corp (STOK) - Net Financial Result|Net Income BLFS (BioLife Solutions, Inc.)|WVE (wavelifesciences.com) - Final Profit|Net Profit MAZE (Maze Therapeutics)|Net Financial Result Sionna Therapeutics, Inc. (SION)|PRME - Company Net Income|TSHA (Taysha Corp) - Company Profit|QURE: Net Profit|Net Income meiragtx.com|Net Income RGNX|SLDB (Solid Biosciences Inc) - Profit After Payment of Taxes|Net Profit OCGN|PACB - Company Net Income|Company Net Income Benitec Biopharma Inc. BNTC|DSGN - Net Income|Rocket Pharmaceuticals, Inc. - Net Profit|FDMT (4DMT) - Company Profit|lexeotx.com (LXEO) - Company Net Income|Company Profit KRRO|EDIT (Editas Medicine, Inc.) - Net Profit|Net Profit silence-therapeutics.com|Net Income PRQR (ProQR Therapeutics N.V.)|Profit After Payment of Taxes CDXS|Net Profit SGMO (Sangamo)|Nautilus Biotechnology, Inc. (NAUT) - Company Net Income|MGX - Company Net Income|Precision BioSciences Inc. (DTIL) - Net Income|generationbio.com (GBIO) - Company Net Income|Profit After Tax BOLD (Boundless Bio Inc.)|Net Income XCUR|Net Profit Celsion Corporation|Company Net Income Phio Pharmaceuticals (PHIO)|Net Financial Result mustangbio.com|TransCode Therapeutics, Inc. - Net Income|Final Profit BNGO|Applied DNA - Net Profit|BLUE - Net Profit|IPA: Net Profit|OMGA - Net Financial Result|Net Income OMIC|RGLS: Final Profit|Net Profit SYRS|Net Financial Result Telesis Bio, Inc|Company Net Income TRACON Pharmaceuticals TCON|UBX: Company Profit